Company: IXHL
Filing Date: 2025-04-07
Form Type: 424B5
Source: 0001213900-25-029414
Chunk: 1

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-07
Form: 424B5
Chunk 1
---
 in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, and/or in any other method permitted by law. If we and A.G.P. agree on a method of distribution
other than sales of shares of our common stock into The Nasdaq Global Market or another existing trading market at market prices, we will
file a further prospectus supplement providing all information about such offering as required by Rule 424(b) under the Securities Act.
While there is no requirement that A.G.P. sell any specific number or dollar amount of shares, it will act as sales agent and use commercially
reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading
and sales practices, on mutually agreed terms between A.G.P. and us. There is no arrangement for funds to be received in any escrow, trust
or similar arrangement.

A.G.P. will be entitled to
compensation at a fixed commission rate equal to 3.0% of the gross sales price per share of common stock issued by us and sold through
it as our sales agent under the Sales Agreement. In connection with the sale of our common stock on our behalf, A.G.P. will be deemed
to be an “underwriter” within the meaning of the Securities Act and the compensation of A.G.P. will be deemed to be underwriting
commissions or discounts. We provide more information about our arrangements with the sales agent in the section entitled “Plan
of Distribution.” We have also agreed to provide indemnification and contribution to A.G.P. with respect to certain liabilities,
including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. The net proceeds
we receive from any sales under this prospectus supplement will be the gross proceeds from such sales less the commissions and any other
costs we may incur in offering the common stock. See “Use of Proceeds” and “Plan of Distribution” for additional
information.

We are an emerging
growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and a smaller reporting company as defined
under Rule 405 of the Securities Act, and, as such, are subject to certain reduced public company reporting requirements. See
‘‘Prospectus Supplement Summary—Implications of Being an Emerging Growth Company and a Smaller Reporting
Company” on page S-4 of this